Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 1
2008 2
2009 2
2010 1
2012 3
2013 4
2014 1
2015 1
2016 3
2017 3
2018 9
2019 13
2020 17
2021 15
2022 17
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.
Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, van Rooij N, van Leerdam ME, Depla A, Smit EF, Hartemink KJ, de Groot R, Wolkers MC, Sachs N, Snaebjornsson P, Monkhorst K, Haanen J, Clevers H, Schumacher TN, Voest EE. Dijkstra KK, et al. Among authors: monkhorst k. Cell. 2018 Sep 6;174(6):1586-1598.e12. doi: 10.1016/j.cell.2018.07.009. Epub 2018 Aug 9. Cell. 2018. PMID: 30100188 Free PMC article.
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.
Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, Broeks A, Sanders J, Herzig P, Zippelius A, Blank CU, Hartemink KJ, Monkhorst K, Haanen JBAG, Schumacher TN, Thommen DS. Voabil P, et al. Among authors: monkhorst k. Nat Med. 2021 Jul;27(7):1250-1261. doi: 10.1038/s41591-021-01398-3. Epub 2021 Jul 8. Nat Med. 2021. PMID: 34239134
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. Niknafs N, et al. Among authors: monkhorst k. Nat Med. 2023 Feb;29(2):440-449. doi: 10.1038/s41591-022-02163-w. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702947 Free PMC article.
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Theelen WSME, et al. Among authors: monkhorst k. JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478. JAMA Oncol. 2019. PMID: 31294749 Free PMC article.
[Treatment of non-small cell lung cancer].
Hopstaken JS, de Ruiter JC, van Diessen JNA, Theelen WSME, Monkhorst K, Hartemink KJ. Hopstaken JS, et al. Among authors: monkhorst k. Ned Tijdschr Geneeskd. 2021 Feb 4;165:D5486. Ned Tijdschr Geneeskd. 2021. PMID: 33651512 Review. Dutch.
X-changing information on X inactivation.
Barakat TS, Jonkers I, Monkhorst K, Gribnau J. Barakat TS, et al. Among authors: monkhorst k. Exp Cell Res. 2010 Mar 10;316(5):679-87. doi: 10.1016/j.yexcr.2010.01.015. Epub 2010 Jan 18. Exp Cell Res. 2010. PMID: 20083102 Review.
The force of HER2 - A druggable target in NSCLC?
Jebbink M, de Langen AJ, Boelens MC, Monkhorst K, Smit EF. Jebbink M, et al. Among authors: monkhorst k. Cancer Treat Rev. 2020 Jun;86:101996. doi: 10.1016/j.ctrv.2020.101996. Epub 2020 Feb 28. Cancer Treat Rev. 2020. PMID: 32135383 Review.
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Douma LH, Lalezari F, van der Noort V, de Vries JF, Monkhorst K, Smesseim I, Baas P, Schilder B, Vermeulen M, Burgers JA, de Gooijer CJ. Douma LH, et al. Among authors: monkhorst k. Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844598 Clinical Trial.
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Weksler B, Bahary N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Goel A, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Li QK, Illei PB, Monkhorst K, Scharpf RB, Brahmer JR, Velculescu VE, Zaidi AH, Forde PM, Anagnostou V. Murray JC, et al. Among authors: monkhorst k. Clin Cancer Res. 2024 Jan 17;30(2):389-403. doi: 10.1158/1078-0432.CCR-23-1469. Clin Cancer Res. 2024. PMID: 37939140 Free PMC article.
Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation.
Menko FH, Monkhorst K, Hogervorst FBL, Rosenberg EH, Adank MA, Ruijs MWG, Bleiker EMA, Sonke GS, Russell NS, Oldenburg HSA, van der Kolk LE. Menko FH, et al. Among authors: monkhorst k. Crit Rev Oncol Hematol. 2022 Aug;176:103642. doi: 10.1016/j.critrevonc.2022.103642. Epub 2022 Mar 5. Crit Rev Oncol Hematol. 2022. PMID: 35257886 Review.
99 results